Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 7Central Nervous System Neoplasms 6Breast Neoplasms 6Pancreatic Neoplasms 5Glioblastoma 5Ovarian Neoplasms 4Neoplasms 4Medulloblastoma 4Glioma 4Sarcoma 3Prostatic Neoplasms 3Osteosarcoma 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Neuroectodermal Tumors, Primitive 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Neoplasm Metastasis 2Multiple Myeloma 2Microphthalmia, Isolated, with Coloboma 5 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Esthesioneuroblastoma, Olfactory 2Diffuse Intrinsic Pontine Glioma 2

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Gemcitabine × CNS × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡